[{"orgOrder":0,"company":"International Flavors and Fragrances","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Phosphatidylserine","moa":"Phosphatidylserine decarboxylase proenzyme, mitochondrial; Scavenger receptor class B member 1; Protein kinase C alpha type; Phosphatidylserine synthase 1; Diacylglycerol kinase gamma; Diacylglycerol kinase delta; Phosphatidylserine synthase 2; Sphingomyelin phosphodiesterase 4; Sphingomyelin phosphodiesterase 3; Phospholipid-transporting ATPase IA","graph1":"Neurology","graph2":"Undisclosed","graph3":"International Flavors and Fragrances","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Gummies","sponsorNew":"International Flavors and Fragrances \/ International Flavors and Fragrances","highestDevelopmentStatusID":"1","companyTruncated":"International Flavors and Fragrances \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"International Flavors and Fragrances","sponsor":"MRM Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"International Flavors and Fragrances","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"International Flavors and Fragrances \/ International Flavors and Fragrances","highestDevelopmentStatusID":"1","companyTruncated":"International Flavors and Fragrances \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"International Flavors and Fragrances","sponsor":"MRM Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Microorganism","year":"2022","type":"Collaboration","leadProduct":"M008","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"International Flavors and Fragrances","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Flavors and Fragrances \/ International Flavors and Fragrances","highestDevelopmentStatusID":"4","companyTruncated":"International Flavors and Fragrances \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"International Flavors and Fragrances","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Probiotic","year":"2020","type":"Collaboration","leadProduct":"Gut-Microbiome","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"International Flavors and Fragrances","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Flavors and Fragrances \/ International Flavors and Fragrances","highestDevelopmentStatusID":"2","companyTruncated":"International Flavors and Fragrances \/ International Flavors and Fragrances"}]

Find Clinical Drug Pipeline Developments & Deals by International Flavors and Fragrances

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : MRM Health, working in conjunction with International Flavors & Fragrances, is advancing the LBP candidate M008 for treating NAFLD/NASH. The proprietary MRM Health CORAL® technology platform and some IFF strains will be combined to develop novel therape...

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          December 12, 2022

                          Lead Product(s) : M008

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Recipient : MRM Health

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 05, 2022

                          Lead Product(s) : Phosphatidylserine

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : Northumbria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The two-year research partnership will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by chemotherapy to potentially improve response rates through modulation of the microbiome.

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Undisclosed

                          July 23, 2020

                          Lead Product(s) : Gut-Microbiome

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Recipient : Rutgers University

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : In collaboration, proprietary MRM Health technology platform and some selected DuPont strains will be combined to develop novel therapeutics based on live bacterial strain combinations.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 19, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : MRM Health

                          Deal Size : $15.1 million

                          Deal Type : Collaboration

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 02, 2018

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Swinburne University of Technology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          July 26, 2018

                          Lead Product(s) : Lactobacillus Paracasei

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : Northumbria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 11, 2018

                          Lead Product(s) : Lpc-37

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Recipient : Daacro

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Probiotic

                          Upfront Cash : Inapplicable

                          March 07, 2017

                          Lead Product(s) : Probion Clinica

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Vastra Gotaland Region

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 31, 2015

                          Lead Product(s) : Lactobacillus Acidophilus

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase II

                          Recipient : Connecticut Children's Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 05, 2015

                          Lead Product(s) : Colorado Diet

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Sponsor : University of Colorado, Denver

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank